What is Dignitana?
Dignitana AB is a Swedish-based medical technology innovator recognized for the development and commercialization of the DigniCap Scalp Cooling System. This specialized medical device is engineered to mitigate chemotherapy-induced alopecia, a common and distressing side effect for patients undergoing treatment for solid tumors such as breast and prostate cancer. By leveraging FDA-cleared technology, the company has established a robust footprint in both the United States and European markets. As a publicly traded entity on the Nasdaq First North Growth Market, Dignitana occupies a critical niche at the intersection of oncology care and patient-centric medical hardware, prioritizing quality of life improvements alongside clinical efficacy.
How much funding has Dignitana raised?
Dignitana has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Dignitana
PPP
Public-Private Partnership
What's next for Dignitana?
With the successful acquisition of $350K, Dignitana is positioned to accelerate its strategic growth initiatives. The company is expected to focus on expanding its clinical footprint and enhancing the market penetration of the DigniCap system. Given the late-stage nature of this financing, the capital will likely be deployed toward scaling commercial operations, optimizing supply chain logistics, and potentially funding further research into the efficacy of scalp cooling across broader oncology indications. As the firm navigates the complexities of the global healthcare landscape, this liquidity provides the necessary runway to solidify its competitive advantage and drive sustainable value for stakeholders in the medical device sector.
See full Dignitana company page
